Dermal Cell News 4.19 June 4, 2018 | |
| |
TOP STORYADAR1-Mediated Regulation of Melanoma Invasion The authors showed that ADAR1 silencing enhances melanoma cell invasiveness and ITGB3 expression. The enhanced invasion was reversed when ITGB3 was blocked with antibodies. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONThrombospondin-1 (TSP1) plays an indirect role in collagen homeostasis through interactions with matrix metalloproteinases and transforming growth factor-β1. Investigators found that TSP1 also affects collagen fibril formation directly. Compared to skin from wild-type mice, skin from Thbs1−/− mice had reduced collagen cross-linking and reduced prolysyl oxidase (proLOX) abundance with increased conversion to catalytically active LOX. [Sci Signal] Full Article A novel, gel-formulated, first-in-class small-molecule inhibitor of GzmB, VTI-1002, was assessed in a murine model of impaired, diabetic burn wound healing. Daily topical administration of VTI-1002 gel for 30 days following thermal injury showed significantly accelerated wound closure, increased decorin protein levels, and collagen organization that was translated into significantly increased wound tensile strength compared to controls. [Exp Mol Med] Full Article SKIN CANCERS & DISORDERSMelanoma Protective Antitumor Immunity Activated by Catalytic DNA Scientists investigated c-Jun expression in human primary and metastatic melanoma. They also explored the role of T cell immunity in DNAzyme inhibition of primary melanoma growth and the prevention of growth in non-treated tumors after the cessation of treatment in a mouse model. [Oncogene] Abstract The authors performed CRISPR/Cas9-mediated treatment on a knockin transgenic mouse model that carried a small indel heterozygous mutation of Krt9, c.434delAinsGGCT, which caused a humanized epidermolytic palmoplantar keratoderma-like phenotype. [Mol Ther Nucleic Acids] Full Article E3 Ligase Trim21 Ubiquitylates and Stabilizes Keratin 17 to Induce STAT3 Activation in Psoriasis Researchers report that keratin 17 could be modified through ubiquitination that controlled its stability and led to the phosphorylation and nuclear translocation of its interactor STAT3, which is a key regulator of cell proliferation in psoriasis. [J Invest Dermatol] Abstract Chitosan-carboxymethyl-5-fluorouracil-folate conjugate was synthesized and processed into submicron particles by spray drying technique. The size, zeta potential, morphology, drug content, drug release, as well as skin permeation and retention, pharmacokinetics, in vitro SKMEL-28 melanoma cell line cytotoxicity and intracellular trafficking profiles of drug/particles were examined, as a function of skin/melanoma cell treatment by microwave at 2450 MHz for 5 + 5 min. [J Invest Dermatol] Abstract Investigators showed that the invalidation of EDAR in mice promotes melanoma progression in a B-Raf mutant background. [Cell Death Differ] Abstract Targeted Delivery of Cell Penetrating Peptide Virus-Like Nanoparticles to Skin Cancer Cells Researchers identified a cell penetrating peptide (CPP) with the sequence NRPDSAQFWLHH from a phage displayed peptide library. This CPP targeted the human squamous carcinoma A431 cells through an interaction with the epidermal growth factor receptor. [Sci Rep] Full Article | |
| |
REVIEWSProtein Kinases Involved in Epidermal Barrier Formation: The AKT Family and Other Animals Scientists describe the roles of multiple protein kinases in the regulation of processes required for epidermal barrier formation. [Exp Dermatol] Abstract Visit our reviews page to see a complete list of reviews in the dermal cell research field. | |
| |
INDUSTRY NEWSArray BioPharma Inc. announced updated results from the Phase III COLUMBUS trial in BRAF-mutant advanced melanoma. [Array BioPharma Inc.] Press Release eTheRNA immunotherapies announced that it has enrolled the first patient in the high dose cohort of its Phase Ib study of ECI-006 as an adjuvant therapy in metastatic melanoma patients. [eTheRNA immunotherapies] Press Release Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration Syndax Pharmaceuticals, Inc. and Nektar Therapeutics announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar’s NKTR-214, a CD122-biased agonist, in combination with entinostat, Syndax’s oral, small molecule class 1 specific HDAC inhibitor, in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 agent. [Syndax Pharmaceuticals, Inc.] Press Release UCB announced that the FDA has approved extending the label for CIMZIA® to include a new indication in adults with moderate-to-severe plaque psoriasis. [UCB] Press Release OliX Pharmaceuticals Inc. announced that it received the Phase I clinical trial authorization with its anti-scar drug, OLX10010, from Medicines and Healthcare products Regulatory Agency in the UK. [OliX Pharmaceuticals Inc.] Press Release Bristol-Myers Squibb Company announced updated results from the Phase III CheckMate -238 trial evaluating Opdivo versus Yervoy in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence following complete surgical resection. [Bristol-Myers Squibb Company] Press Release | |
| |
POLICY NEWSEurope’s Top Science Funder Shows High-Risk Research Pays Off A popular and unusual self-review carried out by Europe’s most prestigious science funder is back. The annual assessment, now in its third year, found that nearly one in five projects by the European Research Council led to a scientific breakthrough. [Nature News] Editorial ‘Right-to-Try’ Law Intended to Weaken the FDA, Measure’s Sponsor Says in Blunt Remarks Sen. Ron Johnson, the author of the federal “right-to-try” law signed by President Trump this week, wants to make one thing clear: His new law is meant to weaken the FDA. “This law intends to diminish the FDA’s power over people’s lives, not increase it,” he wrote in a letter to Commissioner Scott Gottlieb. [STAT News] Editorial China to Crack Down on Fraud in Scandal-Hit Scientific Research amid ZTE Wrangle China has issued the first national guidelines to enforce academic integrity in scientific research and vowed to punish academics and institutes for misconduct such as plagiarism and fabrication of data. [South China Morning Post Publishers Ltd] Editorial Sweden Commits to Open Science with New Open-Access Publishing Deal Swedish researchers can now publish their articles in Frontiers’ Open Access journals through a simplified process that covers publishing fees, thanks to a national agreement announced between Frontiers and the National Library of Sweden, on behalf of the organizations participating in the Bibsam Consortium. [EurekAlert] Editorial
| |
EVENTSNEW Making it Personal: Cancer Precision Medicine Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESAssistant, Associate or Full Professor – Regenerative Medicine (University of San Diego) Postdoctoral Fellow – Skin Stem Cells & Wound Healing (Johns Hopkins University) Postdoctoral Fellow – Cancer Signaling & Trascription (The Francis Crick Institute) Associate Professor or Professor – Skin Cancer (The University of Texas M.D. Anderson Cancer Center) Postdoctoral Fellow – Psoriasis Research (Case Western Reserve University) Postdoctoral Fellow – Skin Cancer Biology (UT Southwestern Medical Center) Postdoctoral/Research Scientist – Cancer Metabolism (Wake Forest Comprehensive Cancer Center) Postdoctoral Researcher – Melanoma (Ghent University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|